Leveraging stem cell technology, genomics and AI to transform mental health and neurology

Leveraging nobel-prize winning technology, a simple blood sample is reprogrammed into induced pluripotent stem cells (iPSCs) – cells that can take on any role, depending on the environment to which they are exposed.

iPSCs in turn are differentiated into patient-specific neurons using a precisely timed exposure to a series of stimuli. Neurons can be directed to differentiate to specific subtypes, according to disease focus, e.g. frontal cortex neurons for major depression.

Neuronal plasticity, the brain’s ability to adapt and rewire, underlies both healthy development and the pathology of mental health conditions. Alterations in neuronal and synaptic plasticity are strongly linked to depression, anxiety, schizophrenia, and other psychiatric disorders.

By studying molecular and morphological markers of plasticity in patient-derived neurons, BrightKaire provides unprecedented insights into how the brain responds to stress, environment, and—most critically—drug treatment.
Our platform integrates computational neuroscience, pharmacogenomic data, and high-resolution cellular assays to quantify these changes, helping clinicians and researchers connect brain biology to personalized treatment response.

We apply computer vision and advanced AI to enable precise and unbiased quantification of morphological features with Machine Learning approaches to develop robust classifiers that assign patients into accurate clinical phenotypes with individualized treatment pathways.

By integrating morphological, molecular, and clinical data trained on large and diverse data sets, BrightKaire generates a multi-feature brain response signature for each patient. This approach represents a new methodology in precision psychiatry—combining iPSC-derived neuron models, neuroplasticity assessment, genetics, and AI-driven analytics to optimize psychiatric treatment selection.